Prenatal screening for specific fetal abnormalities has become a part of routine obstetrical
care. Originally developed in the 1970s for the identification of fetal open neural
tube defects (NTDs) [
[1]
], prenatal screening for NTDs and, more recently, Down syndrome now is offered throughout
the world. In 1995, for example, almost two-thirds of all pregnant women in the United
States had prenatal screening [
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neural tube defects.in: Wald N Leck I Antenatal and neonatal screening. 2nd edition. Oxford University Press, Oxford, UK2000: 61-84
- Maternal serum screening for Down syndrome in the United States: a 1995 survey.Am J Obstet Gynecol. 1997; 176: 1046-1051
- Preface to the second edition.in: Wald N Leck I Antenatal and neonatal screening. 2nd edition. Oxford University Press, Oxford, UK2000: xi-xii
- John Langdon Down: a caring pioneer.The Royal Society of Medicine Press Ltd, London, UK1998
- Natural history of Down's syndrome: a brief review for those involved in antenatal screening.J Med Screen. 1998; 5: 172-177
- Down's syndrome.in: Wald N Leck I Antenatal and neonatal screening. 2nd edition. Oxford University Press, Oxford, UK2000: 85-115
- The relative effects of paternal and maternal age in mongolism.J Genet. 1933; 27: 219-224
- Prenatal diagnosis of Down's syndrome.Lancet. 1968; ii: 220
- The detection of neural-tube defects by screening maternal blood.in: Boue A Prenatal diagnosis. INSERM, France1976: 227-238
- An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities.Am J Obstet Gynecol. 1984; 148: 886-894
- Maternal serum alpha-fetoprotein measurement. A screening test for Down syndrome.Lancet. 1984; i: 926-929
- Combining maternal serum α feto-protein measurements and age to screen Down's syndrome in pregnant women under age 35.Am J Obstet Gynecol. 1989; 160: 575-581
- Antenatal screening for Down's syndrome.J Med Screen. 1997; 4: 181-246
- Low second trimester maternal serum unconjugated estriol in pregnancies with Down's syndrome.Br J Obstet Gynaecol. 1988; 95: 330-333
- Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.Br J Obstet Gynaecol. 1988; 95: 334-341
- Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities.Prenat Diagn. 1987; 7: 623-630
- Maternal serum screening for Down's syndrome in early pregnancy.BMJ. 1988; 297: 883-897
- Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin.Am J Obstet Gynecol. 1990; 163: 1248-1253
- Four marker serum screening for Down's syndrome.Prenat Diagn. 1994; 14: 707-716
- Dimeric inhibin-A as a marker for Down's syndrome in early pregnancy.N Engl J Med. 1996; 334: 1231-1236
- hCG and the free β-subunit as screening tests for Down syndrome.Prenat Diagn. 1998; 18: 235-246
- Assay precision of serum α fetoprotein in antenatal screening for neural tube defects and Down's syndrome.J Med Screen. 2000; 7: 74-77
- Chorionic villus sampling and amniocentesis for prenatal diagnosis.Lancet. 1997; 349: 711-714
- Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy.Prenat Diagn. 1993; 13: 1047-1050
- First trimester screening for aneuploidy: serum biochemical markers.Semin Perinat. 1999; 23: 359-368
- Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.Prenat Diagn. 1997; 17: 821-830
- Free β-hCG as a first trimester marker for fetal trisomy.Lancet. 1992; 339: 1480
- Low maternal serum levels of PAPP-A in the first trimester in association with abnormal fetal karyotype.Br J Obstet Gynaecol. 1993; 100: 324-326
- Nuchal fluid accumulation in trisomy 21 detected by vaginosonography in first trimester.Lancet. 1990; 336: 1133
- Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.BMJ. 1992; 304: 867-869
- Ultrasound in obstetrics and gynecology: an imaging revolution.Contemp Obstet Gynecol. 1998; 43: 67-84
- Manual of obstetric and gynecologic ultrasound.Lippincott-Raven, Philadelphia1997
- Nuchal translucency cannot be used as a screening test for chromosome abnormalities in the first trimester of pregnancy in a routine ultrasound practice.Prenat Diagn. 1996; 16: 797-806
- Effect of study design on the association between nuchal translucency measurement and Down syndrome.Obstet Gynecol. 1999; 94: 864-869
- Screening of maternal serum for fetal Down's syndrome in the first trimester.N Engl J Med. 1998; 338: 955-961
- First trimester screening for aneuploidy: nuchal translucency sonography.Semin Perinat. 1999; 23: 369-381
American College of Obstetricians and Gynecologists (ACOG). Prenatal diagnosis of fetal chromosomal abnormalities [ACOG practice bulletin number 27]. May 2001.
- hCG and the free beta-subunit as screening tests for Down syndrome.Prenat Diagn. 1998; 18: 235-245
- Participation in maternal serum screening following screen positive results in a previous pregnancy.J Med Screen. 2000; 7: 4-6
- Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.N Engl J Med. 1999; 341: 461-467
- Chromosomal abnormality rates at amniocentesis and in live-born infants.JAMA. 1983; 249: 2034-2038
- The natural history of cytogenetically abnormal fetuses detected at midtrimester amniocentesis which are not terminated electively: new data and estimates of the excess and relative risk of later fetal death associated with 47, +21 and some other abnormal karyotypes.Am J Hum Genet. 1989; 45: 855-861
- Risk-based screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin.Prenat Diagn. 1995; 15: 713-723
- Prenatal screening for trisomy 18 in the second trimester.Prenat Diagn. 1990; 10: 546-547
- A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.Prenat Diagn. 2002; 22: 877-879
- Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome.Am J Obstet Gynecol. 1992; 167: 1021-1024
- Second trimester maternal serum and inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.Prenat Diagn. 1998; 18: 1061-1067
- Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement.Prenat Diagn. 2001; 21: 680-686
- Maternal serum hCG levels in triploidy: variability and need to consider molar tissue.Prenat Diagn. 1992; 12: 627-629
- Second-trimester maternal serum analyte levels associated with fetal trisomy 13.Prenat Diagn. 1999; 19: 813-816
- Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.Prenat Diagn. 1999; 19: 1035-1042
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation.Prenat Diagn. 2000; 20: 411-416
- Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation.Prenat Diagn. 2000; 20: 495-499
- Defective cholesterol biosynthesis associated with the Smith Lemli Opitz syndrome.N Engl J Med. 1994; 30: 107-113
- Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (SLO) syndrome fetuses.Am J Med Genet. 1999; 82: 355-358
- Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome.J Med Screen. 2002; 9: 43-44
- Etude des chromosomes somatiques de neuf enfants mongoliens.CR Acad Sci Paris. 1959; 248: 1721-1722
- First and second trimester antenatal screening for Down's syndrome: results of the Serum, Urine and Ultrasound Screening Study (SURUSS).Health Technol Assess. 2003; 7
- Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study.Lancet. 2001; 358: 1665-1667
Article info
Identification
Copyright
© 2003 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
